An interventional study of Retinal vascular assessment using OCTA and SLDF in Patients With Cardiovascular Disease and Healthy Participants, sponsored by University of Erlangen-Nürnberg Medical School. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by University of Erlangen-Nürnberg Medical School · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School — 2 open to participants now, 3 under way, none of them phase 3. Hypertension · University of Erlangen-Nürnberg Medical School.
Among the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 6 with no phase, and was the 13th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →2 of the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School are open now, in 1 country. Recruiting first, the newest first:
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–99
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 4 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 28 across the 11 interventional studies, 27 across the 3 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Erlangen-Nürnberg Medical School is the lead sponsor of 277 studies on the registry; 53 are open to participants now.
3 of the studies in Hypertension by University of Erlangen-Nürnberg Medical School that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07359664University of Erlangen-Nürnberg Medical SchoolOCTA in Cardiovascular Disease and Healthy Controls | 2026-12 |
| NCT06556407University of Erlangen-Nürnberg Medical SchoolEffect of Renal Denervation on Bood Pressure in Patients on Hemodialysis | 2026-12-01 |
| NCT07406191University of Erlangen-Nürnberg Medical SchoolWB-EMS Effects on Cardiometabolic Risk Factors | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective clinical study will involve the non-invasive assessment of retinal vessels using OCTA (Cirrus OCT 6000 AngioPlex) and scanning laser Doppler flowmetry (SLDF) in patients with cardiovascular disease and healthy individuals. The study will be conducted at the Clinical Research Centre (CRC), Department of Nephrology and Hypertension at the University of Erlangen-Nuremberg.
Each patient (32 patients) and healthy individual (32 healthy individuals) undergoes one study visit. After providing informed consent, each patient and healthy individual receives an assessment of their retinal vessels using OCTA and SLDF. In the sub-study of 10 patients with cardiovascular disease, the reliability of the OCTA measurements will be determined. Each patient will receive three study visits (with an OCTA and SLDF assessment on each occasion) on three different days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for patients with cardiovascular disease:
Inclusion Criteria for healthy individuals:
Exclusion criteria for patients with cardiovascular disease:
Exclusion criteria for healthy individuals:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OCTA and SLDF based assessment of retinal vasculature
Diagnostic Test: Retinal vascular assessment using OCTA and SLDF
Assessment of retinal capillary density using OCTA and SLDF
Assessment of reliability of OCTA based assessment of retinal capillary density in patients with CV disease
Assessment of test-retest-reliability between 3 study visits for OCTA based assessment of retinal capillary density in patients with CV disease
Time frame: test-retest-reliability between 3 study visits (between each visit needs to be a time gap of at least 24 hours, all visits will be performed within two weeks)
comparison of OCTA based retinal capillary density between CV diseased patients and healthy controls
comparison of OCTA based retinal capillary density between CV diseased patients and healthy controls
Time frame: one study visit in each group, baseline values at day 1 are compared
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Erlangen-Nürnberg Medical School →